Peptide therapeutics for rare genetic metabolic diseases


Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.


Year Invested: 2010
Location: Boston, Mass.
Visit: www.rhythmtx.com

Recent News

September 28, 2018
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity

September 28, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting

September 25, 2018
Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference

Read More News

Associated Team Members

Neil Exter
Partner